Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ISPC vs MXCT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MXCT Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 4–3 Matrix Metrics)

MXCT Overall Winner 6-Pillar Tally: ISPC 2 – 3 MXCT (1 Tie) Matrix Metrics: ISPC 3 – 4 MXCT

As of Nov 20, 2026, MaxCyte, Inc. (MXCT) is the stronger overall head-to-head candidate over iSpecimen Inc. (ISPC) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). ISPC carries a Unified Composite Score of 41.6/100 (SELL) at $0.46 (N/M Forward P/E, -1455.3% operating margin), whereas MXCT carries 41.7/100 (SELL) at $1.37 (N/M Forward P/E, -85.5% operating margin).

  • Growth vs. Quality Trade-Off: MXCT earns the overall head-to-head edge with a stronger Unified Composite Score (41.7/100 SELL vs. ISPC 41.6/100 SELL) and 1.19β · 96% Vol risk profile, whereas ISPC leads top-line expansion (+128.9% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Defensive Composite Rating Caution: Although MXCT compares more favorably head-to-head, both ISPC (41.6/100 SELL) and MXCT (41.7/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: ISPC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 16.1); meanwhile MXCT trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 55.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ISPC vs MXCT
ISPC NASDAQ
iSpecimen Inc. Common Stock
Services-Commercial Physical & Biological Research
$0.46
-13.58% 1D
Market Cap $3.1M
TTM Revenue $603,744
Forward P/E N/M
Beta / 30D Vol -10.07β · 74% Vol
Unified Composite Score
41.6 / 100 SELL
Tech 25.0 Fund 43.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -29.3%), weak momentum, RSI 16
RSI-14: 16.1 · SMA20: $0.73 · SMA50: $0.97
MXCT NASDAQ Head-to-Head Winner
MaxCyte, Inc. Common Stock
Services-Commercial Physical & Biological Research
$1.37
+7.03% 1D
Market Cap $132.2M
TTM Revenue $34M
Forward P/E N/M
Beta / 30D Vol 1.19β · 96% Vol
Unified Composite Score
41.7 / 100 SELL
Tech 46.0 Fund 52.0 Flow 62.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.1% over 20 days), RSI 55
RSI-14: 55.3 · SMA20: $1.36 · SMA50: $1.25

6-Pillar Scorecard Institutional Category Breakdown (ISPC 2 – 3 MXCT)

Columns: Metric · ISPC · MXCT
1. Valuation Multiples ISPC
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 0.8x 3.9x
2. Growth & Scale MXCT
Revenue Growth (YoY) +128.9% +48.7%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $603,744 $34M
Market Cap $3.1M $132.2M
3. Profitability & Quality MXCT
Gross Margin -42.1% 81.0%
Operating Margin -1455.3% -85.5%
Net Profit Margin 0.0% -81.4%
Return on Equity (ROE) -303.9% -16.9%
4. Balance Sheet & Cash Flow ISPC
Cash Generation (TTM) -$8.7M EBITDA -$24M
Cash Flow Margin N/A -69.2%
Net Cash / Leverage $2.6M Net Cash $2.2M Net Debt (0.11x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MXCT
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Diagnostics & Research Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ISPC (3) vs MXCT (4)
Institutional Metric ISPC MXCT Criterion Row Edge
Market Capitalization
Scale
$3.1M $132.2M Larger Scale MXCT
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+128.9% +48.7% Higher Growth ISPC
Operating Margin (TTM)
Profitability
-1455.3% -85.5% Higher Margin MXCT
Net Profit Margin
Profitability
0.0% -81.4% Higher Margin ISPC
Return on Equity (ROE)
Capital Efficiency
-303.9% -16.9% Higher ROE MXCT
52-Week Range Position
Momentum
5% ($0–$7) 63% ($1–$2) Stronger Trend MXCT
Beta / 30D Volatility
Risk Regime
-10.07β · 74% Vol 1.19β · 96% Vol Lower Realized Risk ISPC
Unified Institutional Score
Composite Signal
41.6 / 100 (SELL) 41.7 / 100 (SELL) Higher Composite Tie
Trailing 12M Revenue (USD)
Operating Scale
$603,744 $34M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-42.1% 81.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.8x EV/Rev N/M PEG · 3.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$8.7M EBITDA ($2.6M Net Cash) -$24M ($2.2M Net Debt (0.11x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MXCT +41.0 pp
ISPC: -45.2% · MXCT: -4.2%
3M Horizon MXCT +69.5 pp
ISPC: -70.94% · MXCT: -1.44%
6M Horizon MXCT +118.5 pp
ISPC: -86.77% · MXCT: +31.73%
1Y Horizon ISPC +9.41 pp
ISPC: -10.0% · MXCT: -19.41%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ISPC Revenue MXCT Revenue ISPC Op. Margin MXCT Op. Margin Margin Leader
FY2019 N/A $10M N/A -93.7% MXCT
FY2020 $10M $20M -29.4% -71.6% ISPC
FY2021 $10M $20M -53.2% -84.3% ISPC
FY2022 $10M $30M -97.9% -95.2% MXCT
FY2023 $10M $20M -112.5% -247.7% ISPC
FY2024 $10M $20M -137.0% -230.5% ISPC
FY2025 $0M $20M -465.4% -247.6% MXCT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ISPC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ISPC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MXCT UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact MXCT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ISPC Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $3.1M market capitalization and -1455.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MXCT Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $132.2M market capitalization and -85.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ISPC vs MXCT Key Questions & Quantitative Answers

As of Nov 20, 2026, MaxCyte, Inc. (MXCT) is the stronger overall head-to-head candidate over iSpecimen Inc. (ISPC) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). ISPC carries a Unified Composite Score of 41.6/100 (SELL) at $0.46 (N/M Forward P/E, -1455.3% operating margin), whereas MXCT carries 41.7/100 (SELL) at $1.37 (N/M Forward P/E, -85.5% operating margin). Growth vs. Quality Trade-Off: MXCT earns the overall head-to-head edge with a stronger Unified Composite Score (41.7/100 SELL vs. ISPC 41.6/100 SELL) and 1.19β · 96% Vol risk profile, whereas ISPC leads top-line expansion (+128.9% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Defensive Composite Rating Caution: Although MXCT compares more favorably head-to-head, both ISPC (41.6/100 SELL) and MXCT (41.7/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: ISPC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 16.1); meanwhile MXCT trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 55.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MXCT leads the Growth & Scale pillar: ISPC posts +128.9% YoY revenue growth and +0.0% YoY earnings growth on $603,744 TTM revenue (-42.1% gross margin, -1455.3% operating margin), compared with MXCT at +48.7% YoY revenue growth and +0.0% YoY earnings growth on $34M TTM revenue (81.0% gross margin, -85.5% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), ISPC cumulative revenue shifted +0.0% while MXCT shifted +100.0%. In operating R&D and SG&A reinvestment, ISPC deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MXCT.

ISPC screens cheaper on headline valuation multiples. ISPC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.8x EV/Revenue (unreported EBITDA margin), whereas MXCT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.9x EV/Revenue (-69.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ISPC (-303.9% ROE) versus MXCT (-16.9% ROE) capital efficiency.

In options market volatility and institutional positioning, ISPC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-10.07β · 74% Vol realized risk). By comparison, MXCT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 96% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.